Fatty Liver & Liver Cirrhosis Are At Epidemic Levels!
- 100,000,000 Americans have a fatty liver. Most don't know it.
- 20,000,000 will develop liver fibrosis disease or NAFLD (nonalcoholic fatty liver disease) as a result.
- 5,000,000 million will progress to liver cirrhosis or NASH (nonalcoholic steatohepatitis) and possibly end stage liver failure.
- Some will be lucky enough to be listed for a transplant, the only cure for late stage liver disease, but 30% of those listed will die waiting. Death by liver failure is long and difficult.
- We want to help you avoid this kind of death by helping you understand how you may be killing yourself slowly. And, what you can do about it.
- If you are already ill, we will do our best to help you with that process.
To improve the diagnosis, treatment & support of Americans with fatty liver, NAFLD or NASH through awareness, education, screening and patient advocacy.
About NAFLD & NASH
> This short video, from John's Hopkins Medicine, gives a good overview of nonalcoholic fatty liver disease. Dr. Saleh Alqahtani, director of clinical liver research and assistant professor of medicine, answers questions about the causes, symptoms and treatments.
> In this video, brought to you by The NASH Education ProgramTM, Stephen A. Harrison, MD, Medical Director of Pinnacle Clinical Research, San Antonio, introduces us to NAFLD (Non Alcoholic Fatty Liver Disease), and more specifically NASH (Non-alcoholic Steatohepatitis). He explains the definition of the disease, as well as its characteristics & the risks induced by its progression. He also highlights how the disease is related to the double epidemic of obesity and diabetes.
We Advocate Early Screening
Typically, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are silent diseases. They have no symptoms. Even if cirrhosis has developed, there are often no symptoms until the liver has become so damaged that the only option is a liver transplant.
There is currently a quick, easy and economical method to screen for fatty liver disease called a FibroScan. Unfortunately, the current medical standards policy is not to screen for liver disease. And, unless you are sick and have symptoms, insurance probably won't pay for the scan, even if you're lucky enough to have a testing system in your area.
The Fatty Liver Foundation is championing a nationwide program to provide liver screening services in cooperation with Liver Care Canada and Echosens, the manufacturer of Fibroscan, to make it possible for people who have a concern for their liver health to get an inexpensive scan. Since insurance doesn't normally cover screening for people who aren't sick yet, it will be on a private pay basis. However, as a nonprofit foundation, we believe we can deliver this service at an affordable price.